Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00748709 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00748709 is a Phase 2 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 20 participants.
The verdict
NCT00748709, a Phase 2 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a Phase II open-label exploratory trial of BIBW 2992 administered to patients with tumors of various histologies found to possess EGFR and/or HER2 gene amplification, or EGFR activating mutations.
Interventions
- DRUG BIBW 2992 (Afatinib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00748709
The ClinicalTrials.gov registry entry for NCT00748709 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BIBW 2992 (Afatinib) is the first listed.
NCT00748709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00748709 about?
NCT00748709 is a clinical study titled "Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.". This is a Phase II open-label exploratory trial of BIBW 2992 administered to patients with tumors of various histologies found to possess EGFR and/or HER2 gene amplification, or EGFR activating mutations.
What is the current status of trial NCT00748709?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2008-10-01.
What interventions are being tested in trial NCT00748709?
The interventions under investigation include: BIBW 2992 (Afatinib) (DRUG).
Who is sponsoring clinical trial NCT00748709?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.